Skip to main content

Google Translate Widget by Infofru

Author Site Reviewresults

Curriculum Vitae

Philip Adib Salem, M.D.

Biography & Bibliography

Philip Adib Salem, M.D. is a world-renowned cancer physician, researcher, educator, author, and international medical statesman. He served on the faculty of the M.D. Anderson Cancer Center in Houston, Texas as a professor of cancer medicine from 1987 to 1991. In 1991, Dr. Salem was appointed Director of Cancer Research at St. Luke’s Episcopal Hospital in Houston, Texas, now known as the Baylor St. Luke’s Medical Center, CHI St. Luke’s Health, where he is currently Director Emeritus of Cancer Research. Also in 1991, Dr. Salem established the Salem Oncology Center, a private cancer facility in the Texas Medical Center in Houston, Texas, where he continues to serve as President. In 2010, St. Luke’s Episcopal Hospital established the Philip A. Salem Chair in Cancer Research to honor Dr. Salem’s contributions to cancer medicine. Dr. Salem has published extensively on Immunoproliferative Small Intestinal Disease and the causative relationship of infection to cancer. His research was also crucial in the development of new anticancer agents.

In addition to being a cancer physician and researcher, Dr. Salem is a renaissance intellectual and author. He has extensively published on Lebanese and Middle Eastern Affairs, and he has also written articles ranging from religion to philosophy to human rights. He advanced the concept that the most sacred human right is the right to health. Eleven books have been written about him and his vision.

Family life and education

Philip Adib Salem was born in Bterram, El-Koura, North Lebanon on July 13, 1941 to Adib Salem and Lamia Malik. He has five brothers and one sister. Dr. Salem and his wife were married in 1973 and have two daughters and a son.

Dr. Salem completed his elementary and secondary education in El Koura, Lebanon. At the age of 16, he matriculated to the American University of Beirut where, in 1961, he earned a Bachelor of Science degree. In 1965, He graduated with a Doctor of Medicine degree from the School of Medicine of the American University of Beirut, in Beirut, Lebanon. After graduating from medical school, Dr. Salem completed 3 years of residency in Internal Medicine at the American University of Beirut Medical Center.

In 1968, Dr. Salem began a fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center in New York, New York. After two years in New York, he moved to Houston, Texas for an additional year of training at the M.D. Anderson Cancer Center.

Dr. Salem as an academician

In 1971, Dr. Salem returned to Lebanon and joined the full-time faculty of the American University of Beirut Medical Center as Assistant Professor and founding Director of the Cancer Research and Treatment Program. In 1978, he was promoted to Associate Professor of Medicine.

In 1987, he returned to the United States and joined the faculty of the M.D. Anderson Cancer Center in Houston, Texas as an Associate Professor of Medicine in the Department of Medical Oncology. In 1990, he was promoted to Professor of Medicine.

In 1991, Dr. Salem was appointed Director of Cancer Research at St. Luke’s Episcopal Hospital in Houston, Texas. Also in the same year, he was appointed Adjunct Professor of Medicine at M.D. Anderson Cancer Center, a position he held until 2000. During his tenure in academic medicine, Dr. Salem served on numerous institutional governance committees.

In 2010, St. Luke’s Episcopal Hospital, now known as the Baylor St. Luke’s Medical Center, CHI St. Luke’s Health, established the Philip A. Salem Chair in Cancer Research “as a lasting tribute to his leadership and vision in the field of oncology.” Dr. Salem continues to hold this chair today. In 2012, after 20 years of being Director of Cancer Research, Dr. Salem was named Director Emeritus.

Dr. Salem as a Physician

During his career, Dr. Salem has treated thousands of cancer patients around the world. Above all else, Dr. Salem considers himself a physician. He embraces the philosophy that, in the practice of medicine, doctors treat people, not diseases. Dr. Salem leads the struggle to rehumanize cancer treatment in America and the world. He believes that knowledge alone is not enough. In addition, patients need love, care, hope, compassion, accessibility to the doctor, and time to talk about their fears, anxieties, and concerns.

Dr. Salem also champions a movement to prohibit government and insurance providers from interfering in the decision-making process in the diagnosis and treatment of cancer. He strongly believes that the doctor should have the liberty to treat patients as he thinks is best and be able to practice without fear of litigation for failure to comply with arbitrary standards and guidelines that may not be appropriate for every patient.

Dr. Salem as a Researcher

Dr. Salem’s research focused on three major areas: Immunoproliferative Small Intestinal Disease (IPSID), lymphomas other than IPSID, and new agents and new treatments in cancer.

In the early 1970s, while at the American University of Beirut Medical Center, Dr. Salem described IPSID as a disease of the small intestine. He demonstrated that a chronic repetitive infectious insult to the gastrointestinal mucosa may eventually lead to inflammatory changes, which, if left untreated, may progress to malignancy.

Dr. Salem and his team also elucidated the process through which histopathologically benign lesions progress to malignancy and described the benign phase of IPSID. He demonstrated that the process of inflammation resulting from a chronic repetitive infectious insult is potentially reversible before it becomes malignant. Dr. Salem and his team showed that if IPSID patients are treated with antibiotics while still in the benign phase, the pathology in the small intestine can be reversed to normal, preventing the transition to cancer. This research was one of the first demonstrations of chemoprevention – the reversal of the neoplastic process before progression to malignancy.

In 2005, the Nobel Prize in Medicine and Physiology went to 2 Australian researchers: Drs. Barry J. Marshall and J. Robin Warren demonstrated the link between infection with H. pylori and peptic ulcer and stomach cancer. In the citation, the Nobel Prize Committee recognized the contributions of prior work in this area, including the IPSID research of Dr. Salem, as a gateway for the research that captured the Nobel Prize.

Dr. Salem and his team have also done extensive research on lymphomas in the Middle East. He has delineated the distinctive features of lymphomas in the Middle East and elucidated how lymphomas in the Middle East differ from those seen in the West. He demonstrated that many lymphomas in the Middle East are extra-nodal, with the intestinal forms being the most common. His team also showed that follicular lymphoma is rare in the Middle East and that the most common lymphoma in children there is Burkitt’s lymphoma.

Dr. Salem also developed a new method for the delivery of the cancer drug Cisplatinum that substantially reduced its toxicity to the kidney. Instead of giving the whole dose of the drug in one injection, Dr. Salem and his team fractionated the dose over five days. This fractionation was useful in helping patients tolerate the drug and in protecting the kidney from irreversible damage. This work served as the basis for the Cisplatinum dosing protocols that are currently used around the world, and for the fractionation of the dose of another cancer drug, Adriamycin.

Additionally, Dr. Salem has explored the efficacy of administering anti-cancer agents directly to the liver through intra-arterial hepatic infusion. This work demonstrated success in treating liver cancer including primary and metastatic liver cancer.

Dr. Salem has also been an active participant in clinical trials on the chemoprevention of cancer. He was the Principal Investigator at St. Luke’s Hospital for a national study investigating the use of Tamoxifen and Raloxifene in preventing breast cancer in high-risk women. He also participated in studies investigating the use of Cis-retinoic Acid, a synthetic form of vitamin A, in the prevention of lung, and head and neck cancers. He continues to conduct research in this area.

Most recently Dr. Salem has developed a new strategy for the treatment of advanced cancer, which is called ICTriplex, This strategy utilizes the three approaches to cancer therapy, and the combination of Immunotherapy, chemotherapy plus targeted treatment. It has been shown to be extremely effective in the treatment of advanced disease. On the occasion of the Annual Meeting of the American Society of Clinical Oncology( ASCO) which was held in Chicago from May 31-June 3rd, 2024, The ASCO Post which is the official publication of ASCO, has featured Dr. Salem in its edition of June 3, 2024, as one of the leaders in cancer care and research, and published a long article about his professional life.

Dr. Salem was director of Cancer Research at Baylor St. Luke’s Medical Center from September 1991 until 2012. Thereafter he became director emeritus of cancer research.

Dr. Salem as an Educator

In addition to his roles as a physician and researcher, Dr. Salem has also been an educator. While at the American University of Beirut Medical Center in the 1970s, Dr. Salem established the first fellowship training program in cancer treatment and research in the Middle East.

Throughout his career, Dr. Salem trained hundreds of medical students, residents, and fellows. He also coordinated and chaired multidisciplinary tumor conferences at the various hospitals at which he worked, and he participated in hundreds of conferences around the world on cancer research and treatment. He considers public and professional education as the key to the conquest of cancer.

Dr. Salem as an Author and subject of books

The following books have been published:

  1. “Philip Salem – The Man, The Homeland, The Science” (Arabic). Boutros Indari, Author. Dar Al-Nidal, Beirut, 2004.
  2. “Cancer, Love and the Politics of Hope – the life and vision of Philip A. Salem M.D.” (English). Frances Mourani and Boutros Indari, Authors. Quartet Books Ltd, London, 2012.
  3. “Philip Salem the Rebel, the Scientist and the Humanist” (Arabic). Maha Samara, Author. Dar Al Saqi and Dar Annahar, Beirut, 2013.
  4. “Philip Salem: Healing the Body, Healing the Soul” (Arabic). Antoine Noujaim, Author. Arts, Sciences, and Technology University, Lebanon, 2014.
  5. “Philip Salem: by their Pens” (Arabic and English). Assaad Khoury, Editor. Maoushy and Zakaria Publisher, Beirut, 2014.
  6. “From the Conquest of Cancer to the Resurrection of Lebanon” (Arabic) Dr. Philip A. Salem, Author. Notre Dame University, Lebanon.
  7. “The Message of Lebanon and Its Meaning” (Arabic) authored by Dr. Philip Salem and published by Hachette-Antoine, was launched in Beirut in June 2017.
  8. “DEFEATING CANCER – knowledge Alone is not enough” (English) authored by Dr. Philip A. Salem and published by Quartet Books LTD, London England, was launched in Beirut On July 24, 2018.
  9. “Professor Philip Salem and The Cancer of Sectarianism” (Arabic) authored by a Lebanese writer Mr. Jean Dayeh, was published in Beirut, Lebanon in November 2018. The book focuses on the significance of separating religion from the state and separating religion from education. Was launched in Beirut in Jan. 2019.
  10. “Knowledge Leads you to God” was published in Arabic by Meouchi Publishing House, Lebanon in December 2019. The introduction to the book was written by the Cardinal Patriarch Bechara Boutros al-Rahi, the Maronite Catholic Patriarch of Antioch.
  11. “Lebanese Nationalism in the Vision of Philip Salem”. On the occasion of the Centennial of the state of greater Lebanon. The book is published in Arabic in Beirut, Lebanon by Meouchi Publishing House. Authored by the journalist Mr. Assaad Khoury. Sept 2020.
  12. “The Philosophy of Rebellion and Revolution”. Published in Arabic, in Beirut, Lebanon by Dar Sa’er Al Mashriq, “All Orient” publishing house. Launched during a book signing ceremony held at Notre Dame University (NDU). Speakers were Fr. Bechara Khoury (president of NDU), Melhem Khalaf (member of the Lebanese parliament), Anwar Harb (chief editor of Annahar, Australia), and Colette Saliba (writer). July 21, 2022.
  13. “Philip Salem the Stance and the Vision”, published in Arabic, in Beirut, Lebanon, authored by Mr. Assaad Khoury, a Lebanese Journalist, June 2024.
  14. “Philip Salem, A life devoted in defense of Lebanon”, published in Arabic in Lebanon, authored by Mr. Assaad Khoury, a Lebanese Journalist. July 2025.

Dr. Salem as an International Medical Statesman

Dr. Salem served on a White House Advisory Committee on Health Care between 1989-1994. He has an official agreement with Mexico to train Mexican cancer doctors in cancer research and treatment regularly. He has established many collaborative programs in Italy, particularly in Milan, Rome, Napoli, and Palermo. In appreciation for his contributions to Mexico and Italy, he has received many awards and medals from their governments and cancer institutions. He is also a consultant to many countries in Latin America, Europe, and the Middle East on the development of cancer programs.

During his tenure at the American University of Beirut, Dr. Salem has also served as President of the Lebanese Cancer Society, Chairman of the Lebanese National Unit for Cancer Research, and Secretary General of the Federation of Middle East Cancer Organizations. In the 1980s, he served as an ADHOC Chairman of the International Faculty of the UICC Post Graduate Course on Chemotherapy. In the 1990s, he was President of the Arab American Cancer Foundation. Dr. Salem is an active member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the European Society of Medical Oncology (ESMO), the Texas Medical Oncology Society (TMOS). He has served on the editorial boards and as a reviewer for numerous cancer research journals in the United States, Latin America, Europe, and the Middle East.

The Salem Oncology Center

Dr. Salem established The Salem Oncology Center in 1991 and continues to serve as its President today.

The Salem Oncology Center is a private cancer facility located in the Texas Medical Center, at 6624 Fannin Street, Houston, Texas. The Center is committed to excellence in the treatment of cancer patients, and to the philosophy of embracing patients with love and compassion.

The Philip Salem Foundation

After 45 years of practicing cancer medicine, Dr. Salem founded the Philip Salem Foundation.

Dr. Salem believes that the only way to conquer cancer is through research. The Philip Salem Foundation was born out of his passion for research, patient care, and educating physicians, patients, and the public about cancer.

His Vision for the Philip Salem Foundation includes:

  • Research. Support and promote cancer research that will contribute to the development of targeted therapy drugs, gene therapy, and cancer prevention.
  • Training. Support training of doctors, nurses, and paramedical professionals engaged in the treatment of cancer, including extended training programs for practicing physicians.
  • Education. Support the education of professionals and the public in the diagnosis and treatment of cancer, through the publication of books, leaflets, articles, and other materials, and the conduct of seminars and lectures.

The Philip Salem Foundation is a 501(c) 3 non-profit organization in the State of Texas.

Special Honors

The Philip Salem Center for Lebanese Political Studies and Research

This center was established at Saint Joseph University in Beirut, Lebanon, on July 16, 2024. The center will be physically established at the main campus of the university. It will house the personal library of Dr. Salem and a team of academicians to examine, evaluate, and conduct research relating to political issues in Lebanon. Also, a professor will carry the name of the Philip Salem Center professor. In addition, every year an award will be given to a distinguished graduate in the Medical School.

The Philip Salem Center for Lebanese Heritage

The Lebanese American University (LAU), which is also one of the most prestigious universities in Lebanon and which is chartered in NY, decided in July 2025 to name the Center for Lebanese Heritage at the university after Dr. Salem. This center focuses on the Lebanese heritage, and it promotes this heritage to the Lebanese residing in Lebanon and to the Lebanese diaspora.

The Philip Salem Conference Center

Baylor St. Luke’s Medical Center and the Dan Duncan Comprehensive Cancer Center decided in August 2025 to name the conference center at the Dan Duncan Cancer Center the Philip Salem Conference Center. This conference center is composed of 11 conference Rooms and is probably the largest conference space in the Texas Medical Center.

Honors and Awards

  • Medal of Achievement, in recognition of research on Mediterranean lymphoma (IPSID), Italian Association of Pathologists, 1981
  • Citation, for contributions to the success of the journal, by Mary M. Bissey, assistant editor of the journal Cancer, 1986
  • Who’s Who in Lebanon, 1985-present
  • Who’s Who in the Arab World, 1985-present
  • Member, Ad hoc White House Advisory Committee on Health Care, appointed by committee chair Dr. Burton Lee, 1989-1994
  • Honoree, for contributions to cancer research, Annual Convention of St. Jude Children’s Research Hospital, 1993
  • Republican Senatorial Medal of Freedom, 1994
  • Goodwill Ambassador for the City of Houston, 1994
  • Honoree, for contributions to cancer medicine, American University of Beirut, 1994
  • Medal of the Cedars, Lebanon, 1994
  • "Man of the Year in Medicine," "ALMAJALLA," International Arab Weekly News Magazine, Arab Press House, London, England, 1994
  • National Directory of Who’s Who, 1995
  • International Who’s Who of Professionals, 1995
  • “Outstanding cancer physician of the year,” Middle East Broadcasting Television Station, London, 1995
  • Life Member, National Registry, Who’s Who, 1997
  • Honoree, for contributions to cancer medicine and service to Lebanon and mankind, British-Lebanese Association, London, 1997
  • Ellis Island Medal of Honor by the National Ethnic Coalition Organizations (NECO), for “exceptional humanitarian efforts and outstanding contributions to American science,” 1998
  • Member, Ellis Island Medal of Honor Society, 1998
  • Commendatore of the Order to the Merit of the Italian Republic (OMRI), 1998
  • Distinguished 20th Century Republican Leader, Republican Members of the United States Senate, 1998
  • Honoree, for contributions to medicine, Arabic literature, philosophy, and politics, Cultural Movement of Antelias, Lebanon, 1999
  • Khalil Gibran International Award, Arabic Heritage League, Sydney, Australia, 2000
  • Arab American of the Year Award, Arab Community Center for Economic and Social Services (ACCESS), Dearborn, Michigan, 2000
  • America’s Top Doctors, Castle Connolly Guide, Castle Connolly Medical Ltd., 2001-2007
  • Who’s Who in Executives & Businesses, Nationwide Register’s Who’s Who, 2001
  • “Intellectual of the Year,” Diwan Ahl Al-Qalam, Beirut, Lebanon, 2002
  • Decorated with the highest civilian honor by the President of Lebanon, 2002
  • Arab American Cultural and Heritage Award, Arab American Cultural and Heritage Center, Houston, Texas 2002
  • “Man of the Month,” Arrajol Magazine, Saudi Publishing and Distributing Company, London, England. Issue no. 125, pages 18-31, 2003
  • Lifetime Achievement Award, Arab Center Congress, 2003
  • Featured in the cover story entitled “Dr. Philip Salem, Pivotal Contributor to Cancer Research,” Arab American Affairs magazine, Volume 32, Number 212, Pages 40-43, 2004
  • Lifetime Achievement Award, American Lebanese National Movement, 2005
  • Honoree, 12th International Meeting of the Lebanese World Cultural Union, Beirut, Lebanon, 2005
  • American Lebanese Medical Association Scientific Achievement Award, American Lebanese Medical Association, 2006
  • “The Scientist of the Year,” La Fondazione Foedus Cultura Impresa Solidarietà, Italy, 2006
  • “Intellectual of the Year,” MBC television station, Dubai, UAE, 2008
  • Honoree, for contributions to medicine and Lebanon, World Lebanese Cultural Union, 2009
  • Marquis Who’s Who in America, 2010
  • Philip A. Salem Chair in Cancer Research established in honor of Dr. Salem, St. Luke’s Episcopal Hospital, Houston, Texas, 2010
  • Honorary Doctorate in Humane Letters for contributions to medicine, Arabic literature, and philosophy, Lebanese American University, Lebanon, 2010
  • Lifetime Achievement Award, Arab American Community and Cultural Centre, Houston, Texas, 2010
  • Member of the Board, Arab Thought Forum, 2010
  • Featured in the book “Featured Faculty Members of the American University of Beirut” as one of the best 15 faculty members in the history of the university. Michel Jeha, Author, Nelson House for Publishing and the American University of Beirut Alumni, 2010
  • Distinguished Lifetime Achievement Award, Rene Moawad Foundation, 2012
  • Honored, for contributions to cancer medicine and the cause of Lebanon, and as the heir of Dr. DeBakey’s legacy: Excellence in Medicine, Beirut International Award Festival, 2012
  • Honoree, for 20 years of service as Director of Cancer Research, St. Luke’s Episcopal Hospital, Houston, Texas 2012
  • Honoree, as a physician, intellectual and Lebanese nationalist, Lebanese Circle of Intellectuals (Montada al Shira’ al Fikri), Beirut, 2012
  • Honoree, for contributions to medicine, literature, and politics, Lions Economic Forum committee, Beirut, 2013
  • Honoree, Lebanese Welfare Association for the Handicapped, 2013
  • Honorary Doctorate in Humane Letters for contributions to medicine, Arabic literature, and philosophy, Notre Dame University of Lebanon, 2013
  • The Philip A. Salem Award in Nursing Excellence was established in honor of Dr. Salem, Notre Dame University of Lebanon, 2013
  • Honoree, University of Arts, Science and Technology, Beirut, 2014
  • Honoree, as a distinguished cancer physician and established author and intellectual. The Cultural Council and the Municipality of Byblos, Lebanon, 2014
  • Supreme Medal of Excellence, FOEDUS, The Italian Foundation of Culture and Science, 2015
  • Appointed Member of the Board of Trustees of Notre Dame University, Lebanon, April 2016.
  • Honorary Doctorate in Humane Letters for contributions to medicine. The Lebanese University of Lebanon, Nov. 16, 2017.
  • Baylor St Luke’s Medical Center established a bi-annual lecture series that carries his name. This is in honor of his contributions to cancer medicine and research. The first inaugural lecture was given on April 12, 2018, by Dr. Issam Raad, Chief of Infectious Disease at M. D. Anderson Cancer Center, in February 2018.
  • The prestigious Annahar Newspaper of Beirut featured Dr. Salem on the front page. Never before in the history of the newspaper was a man featured in this manner. This was in recognition of completing 50 years in cancer medicine and research, on July 23, 2018.
  • The president of Lebanon, Michel Aoun, bestowed on Dr. Salem the highest honor that the president can bestow on anybody. The medal was “The Lebanese Golden Life Achievement Award, Highest degree”. This medal was awarded to Dr. Salem in a ceremony held at Phoenicia Hotel in Beirut, Lebanon, on July 24, 2018.
  • Interview with National Fox News in New York on January 16, 2019, about the recently published book, “DEFEATING CANCER, Knowledge Alone is not enough”. The interviewer was Dr. Danny Alvarez. This interview has been aired many times all over the world.
  • Dr. Salem was honored on July 26, 2022, in Beirut, Lebanon by the World Lebanese Cultural Union (WLCU), with the Hassan Kamel Al-Sabbah award, which is the highest award that the WLCU could grant anybody. This was done during a ceremony at the Le Maillon restaurant in Beirut. The current president of the WLCU is Mr. Fawaz Abbas.
  • “The International Award of the Pride of Arabs in Cancer Research” was granted to Dr. Philip Salem on Dec 13, 2022, in Dubai by the authorized council for granting scientific awards. The award was granted to Dr. Salem for his life achievements in cancer research but in particular for two of them:
    • The concept is that repeated microbial infections may eventually lead to cancer.
    • The new concept is that a combination of Immunotherapy plus chemo plus targeted therapy in advanced cancer is an extremely effective new treatment.
  • Documentary on Dr. Charles Malek and Dr. Philip Salem. On Monday, January 2, 2023, at 11 a.m. Houston time (7 p.m. Beirut time), Noursat, TV Lumiere – the specific television station of Tele Lumiere, (the voice of the catholic church all over the world), aired a 12-minute documentary on two men from Lebanon. Dr. Charles Malek and Dr. Philip Salem. The title of the documentary was “Lebanon and Man”. Charles Malek and Philip Salem. Half of the documentary was on Charles Malek and his contributions to the UN Declaration of Human Rights. The remaining half was on Dr. Salem and his achievements in cancer medicine. The narration on the Malek section was a speech of mine, that I delivered at a conference on Charles Malek which was held in Sydney Australia, on Dec 12, 2022. and my remarks were the content of a video that I prepared for the Fakhr Al Arab Award in Cancer Research ceremony that was held in Dubai, UAE on December 13, 2022. The award was “The International Award of the Pride of Arabs in Cancer Research”.
  • July 7, 2023, Dr. Salem was honored by the University of St. Joseph (USJ) in Beirut and he was the commencement speaker for the graduates of the School of Medical Sciences.
  • February 4, 2024. On the occasion of World Cancer Day which is on February 4 every year. This year the basic theme was progress in the treatment of advanced cancer. The media in the United States and the Daily Mail of London featured Dr. Salem as the architect of the new strategy for the treatment of advanced cancer which is named ICTriplex. The Daily Mail of London featured Dr. Salem with an article entitled “Is Dr. Salem the world’s best cancer doctor?”.
  • June 03, 2024. On the occasion of the Annual Meeting of the American Society of Clinical Oncology(ASCO) which was held in Chicago, May 31-June 3rd, 2024, The ASCO Post, the official publication of ASCO, featured in its edition of June 3, 2024, Dr. Salem as one of the leaders in cancer research and care, and published in the same issue a 3-page interview with him.
  • In July 2025 the University of Saint Joseph established the Philip Salem Excellence Award. This award is given to a distinguished student in the graduate class of the medical school at the University USJ, and Dr. Salem personally gave this award on July 8, 2025.

Bibliography

Philip A. Salem, M.D.

Publications

  1. Sykes MP, Salem P, Joffe B. Topical 5-fluorouracil: variability of effective dosage and duration of reaction. J Am Geriatr Soc 1971; 12:977-982.
  2. Salem PA. Pulmonary changes and bleomycin. Cancer Bull 1971(Jul-Aug);23(4):68-69.
  3. Hart JS, Ho DH, George SL, Salem P, Gottleib JA, Frei E 3rd. Cytokinetic and molecular pharmacology studies of arabinosylcytosine in metastatic melanoma. Cancer Res 1972; 32:2711-2716.
  4. Luna MA, Bedrossian CW, Lichtiger B, Salem PA. Interstitial pneumonitis associated with bleomycin therapy. Am J Clin Pathol 1972(Nov);58(5):501-510.
  5. Salem P. The rational approach to the cancer patient. (Editorial) J Med Liban 1972; 25:7-9.
  6. Salem PA, Omura G, Clarkson B. Clinicopathological correlations in acute leukemia. Chapter in the proceedings of the Arab Middle East Medical Conference, Syria 1974: pp 221-243.
  7. Salem PA. The multi-disciplinary approach to cancer. J Med Liban 1975;28(1):5-8.
  8. Salem PA. Advances in cancer chemotherapy. J Med Liban 1975;28(1):9-24.
  9. Hajj A and Salem P. Staging in Hodgkin's disease. Techniques and impact on therapy. J Med Liban 1975; 28:79-87.
  10. Salem PA, Nassar V, Hajj A, Balikian G, Alami S, Shamaa M, Salem A. [Clinical Statement. What is called “Mediterranean Lymphoma” at the Hospital Center of the American University in Beirut]. J Med Liban 1975;28(2):215-224.
  11. Kaufman R, Salem P, Wittes RE. Responsiveness to endocrine manipulation in breast cancer after "prophylactic" castration. J Surg Oncol 1977; 9:39-43.
  12. Salem PA, Bodey GP, Burgess MA, Murphy WK, Freireich EJ. A phase I study of pyrazofurin. Cancer 1977(Dec);40(6):2806-2809.
  13. Salem PA, Nassar VH, Shahid MJ, Hajj AA, Alami SY, Balikian JB, Salem AA. "Mediterranean abdominal lymphoma," or immunoproliferative small intestinal disease. Part I: clinical aspects. Cancer 1977(Dec);40(6):2941-2947.
  14. Salem PA. Oncology overview. Monograph. Selected abstracts on Platinum coordination complexes as anticancer agents. US Department of Health, Education, and Welfare, Service of the International Cancer Research Data Bank (ICRDB) 1977(Oct).
  15. Yap HY, Salem P, Hortobagyi GN, Bodey GP Sr, Buzdar AU, Tashima CK, Blumenschein GR. Phase II study of cis-dichlorodiammineplatinum (II) in advanced breast cancer. Cancer Treat Rep 1978; 62:405-408.
  16. Salem P, Hall SW, Benjamin RS, Murphy WK, Wharton JT, Bodey GP. Clinical phase I-II study of cis-dichloro-diammineplatinum (II) given by continuous Iv infusion. Cancer Treat Rep 1978; 62:1553-1555.
  17. Nassar VH, Salem PA, Shahid MJ, Alami SY, Balikian JB, Salem AA, Nasrallah SM. “Mediterranean abdominal lymphoma” or immunoproliferative small intestinal disease. Part II: pathological aspects. Cancer 1978(Apr);41(4):1340-1354.
  18. Loo TL, Hall S, Salem PA, Benjamin R, Lu K. Clinical pharmacological and toxicological studies of cis-diamminedichloro-platinum (II) by continuous intravenous infusion. Biochemie 1978; 60:957-960.
  19. Nassar NT, Zurayk HC, Salem PA. Smoking patterns among university students in Lebanon. J Am Coll Health Assoc 1980(Apr);28(5):283-285.
  20. Issa PY, Salem PA, Brihi E, Azoury RS. Eosinophilic granuloma with involvement of the female genitalia. Am J Obstet Gynecol 1980(Jul 1);137(5):608-612.
  21. Salem PA, Jabboury KW, Khalil MF. Severe nephrotoxicity: a probable complication of cis-dichlorodiammineplatinum (II) and cephalothin-gentamicin therapy. Oncol 1982;39(1):31-32.
  22. Salem PA, Tabry I, Parsi M, Brihi E. Histiocytic lymphoma presenting with portal hypertension and bleeding esophageal varices: a case report. J Surg Oncol 1982(May);20(1):37-40.
  23. Abdel Karim FW, Ayash RE, Allam C, Salem PA. Pulmonary fibrosis after prolonged treatment with low-dose cyclophosphamide. A case report. Oncology 1983;40(3):174-176.
  24. Mooradian AD, Allam CK, Khalil MF, Salti I, Salem PA. Anaplastic transformation of thyroid cancer: report of two cases and review of the literature. J Surg Oncol 1983(Jun);23(2):95-98.
  25. Penta JS, Muggia FM, Salem PA. Cisplatin in cancer therapy -- Optimization of treatment regimens and toxicity protection. Chapter 6 in Cancer Chemotherapy I. Muggia FM, Editor. Martinus Nijhoff, The Hague 1983; pp 149-169.
  26. Salem P, Khalyl M, Jabboury K, Hashimi L. Cis-diamminedichloroplatinum (II) by 5-day continuous infusion. A new dose schedule with minimal toxicity. Cancer 1984; 53:837-840.
  27. Salem PA. Systemic therapy of bladder cancer. Prog Clin Biol Res 1984;162B:95-105.
  28. Hashimi LA, Khalyl MF, Salem PA. Supraventricular tachycardia. A probable complication of platinum treatment. Oncology 1984;41(3):174-175.
  29. Salem PA, Hashimi L, Anaissie E, Khalyl M, Allam C. Primary intestinal lymphoma of adults in the Middle East. J Chemioterapia 1985; 43:1352.
  30. Anaissie E, Geha S, Allam C, Jabbour J, Khalyl M, Salem P. Burkitt's lymphoma in the Middle East. A study of 34 cases. Cancer 1985; 56:2539-2543.
  31. Salem PA, Habboubi N, Anaissie E, Brihi ER, Issa P, Abbas JS, Khalyl MF. Effectiveness of cisplatin in the treatment of anal squamous cell carcinoma. Cancer Treat Rep 1985(Jul-Aug);69(7):891-893.
  32. Anaissie E, Geha S, Allam C, Jabbour J, Khalyl M, Salem P. Burkitt's lymphoma in the Middle East. In Burkitt's Lymphoma: A Human Cancer Model. Lenoir GM, O'Connor GT, Olweny CLM, Editors. IARC Scientific Publications, Lyon. 1985; 60:129-134.
  33. Salem PA, El-Hashimi L, Anaissie E, Khalyl M, Allam C. Immuno-proliferative small intestinal disease. Chapter in Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances. Cavalli F, Bonadonna G, Rozencweig M, Editors. Martinus Nijhoff Publishing 1985; pp 269-277.
  34. Salem P, Khalyl M, Jabboury K, Hashimi L. The 5-day continuous infusion of cis-platinum: An update on toxicity pattern. Chapter in Clinical Applications of Continuous Infusions, Chemotherapy, and Concomitant Radiation Therapy. Rosenthal CJ and Rotman M, Editors. Plenum Press, New York 1985: pp 101-105.
  35. Salem P, Anaissie E, Allam C, Geha S, Hashimi L, Ibrahim N, Jabbour J, Khalyl M. Non-Hodgkin's lymphomas in the Middle East. A study of 417 patients with emphasis on special features. Cancer 1986; 58:1162-1166.
  36. Salem PA. Non-Hodgkin's lymphomas. Management strategy and future research. J Med Liban 1986;36(3):107-115.
  37. Salem P, El-Hashimi L, Anaissie E, Geha S, Habboubi N, Ibrahim N, Khalyl M, Allam C. Primary small intestinal lymphoma in adults. A comparative study of IPSID versus non-IPSID in the Middle East. Cancer 1987; 59:1670-1676.
  38. Shikhani A, Samara M, Allam C, Salem PA, Lenhard R. Primary lymphoma in the salivary glands: report of five cases and review of the literature. Laryngoscope 1987; 97:1438-1442.
  39. Salem PA. Mediterranean Abdominal Lymphoma (Immunoproliferative Small Intestine Disease). Chapter 36 in Manual of Adult and Paediatric Medical Oncology. Monfardini S, Brunner K, Crowther D, Eckhardt S, Olive D, Tenneberger S, Veronesi A, Whitehouse J, Wittes R, Editors. Springer-Verlag, Inc, New Jersey 1987: pp 375-377.
  40. Ibrahim NK, Khouri FP, Salem PA. VP-16-based regimen in adult acute nonlymphoblastic leukemia. Oncology 1988;45(1):21-23.
  41. Kim EE, Abello R, Wallace S, Coan J, Salem PA. Gated MRI imaging of malignant cardiac tumors. Mag Resonance Imaging 1988; 6:129.
  42. Kim EE, Wallace S, Abello R, Coan JD, Ewer MS, Salem PA, Ali MK. Malignant cardiac fibrous histiocytomas and angiosarcomas: MR features. J Comput Assist Tomogr 1989(Jul-Aug);13(4):627-632.
  43. Zakhem A, Aftimos G, Kreidy R, Salem P. Malignant struma ovarii: report of two cases and selected review of the literature. J Surg Oncol 1990; 43:61-65.
  44. Mavligit GM, Zukiwski AA, Gutterman JU, Salem P, Charnsangavej C, Wallace S. Splenic versus hepatic artery infusion of interleukin-2 in patients with liver metastases. J Clin Oncol 1990;8:319-324.
  45. Mavligit GM, Zukiwski AA, Salem PA, Lamki L, Wallace S. Regression of hepatic metastases from gastrointestinal leiomyosarcoma after hepatic arterial chemoembolization. Cancer 1991(Jul 15);68(2):321-323.
  46. Karr RA, Best CG, Salem PA, Toth, BB. Synovial sarcoma metastatic to the mandible: report of two cases. J Oral Maxillofac Surg 1991(Dec);49(12):1341-1346.
  47. Gonzalez R, Salem P, Bunn PA Jr, Zukiwski AA, Lamb R, Benjamin RS, Spitler L, Wedel N, Robinson WA. Single-dose murine monoclonal antibody ricin A chain immunotoxin in the treatment of metastatic melanoma: a phase I trial. Mol Biother 1991; 3:192-196.
  48. Salem PA. Mediterranean abdominal lymphoma. A new pathological classification. Chemotherapia 1992(Aug).
  49. Salem PA. Evolution of chemotherapy in the treatment of sarcomas. Chemotherapia 1992(Aug).
  50. Jones D, Levin B, Salem P. Primary Small Intestinal Lymphomas. Chapter 69 in Gastrointestinal Disease: Pathophysiology/ Diagnosis/ Management, 5th Edition. Sleisenger MH and Fordham JS, Editors; Scharschmidt BF and Feldman M, Associate Editors. WB Saunders Company 1993: pp 1378-1392.
  51. Kim EE, Cho J-S, Salem P, Ro JY, Mountain CF. Case Report: Mediastinal synovial sarcoma. Cancer Bulletin 1993; 45:370-372.
  52. Salem P and Jones, D. Treatment of Malignant Neoplasms of the Mucosa-Associated Lymphoid Tissues (MALT). Chapter 47 in The Non-Hodgkin's Lymphomas, 2nd Edition. Ian Magrath, Editor. Arnold 1997: pp 989-1005.
  53. Salem PA. Breast Cancer: Advances in Early Detection and Prevention. Medical Interface 1996(Aug);9(8).
  54. Salem PA. Recapturing compassion in medicine: A book review. In Medicine: Preserving the Passion in the 21st Century, 2nd edition. Texas Medicine 2005(Sep): pp13-14.
  55. Salem PA and Estephan FF. Immunoproliferative small intestinal disease: current concepts. Cancer J 2005(Sep-Oct);11(5):374-382.
  56. Salem PA. Lymphoma: diagnosis and treatment. St. Luke’s Cancer Program 2007 Annual Report. 2007(Dec).
  57. Mach CM, Kim J, Soibam B, Creighton CJ, Hawkins SM, Zighelboim I, Goodfellow P, Gunaratne PH, Odunsi K, Salem PA, Anderson ML. Novel MicroRNAs regulating proliferation and apoptosis in uterine papillary serous carcinomas. Cancer Lett 2013(Jul 28);335(2):314-322.
  58. Salem PA, Jabboury K, Stenoien R, Wheeler T, Valerio MR. Immune checkpoint inhibitors combined with chemotherapy and targeted therapy yield high remission rates in advanced cancer diseases. Trends in Cancer Research. Vol 15; Dec 2020; Pgs 49-62.

Presentations and Abstracts

  1. Kaufman RJ and Salem PA. Recurrent mammary cancer - endocrine management after "prophylactic castration." 10th Intl Cancer Cong, Abstract #835, 6:517, 1970.
  2. Salem PA and Sykes M. Effect of topical 5-fluorouracil on normal skin. 10th Intl Cancer Cong, Abstract #798, 6:493, 1970.
  3. Hart J, Ho D, Salem PA, Frei E. Clinical and kinetic evaluation of continuous 5-day Ara-c in melanoma. Am Assoc Cancer Res, Abstract #401, 13:101, 1972.
  4. Salem PA, Hajj A, Shahid M, Azzam S, Alami S. Experience with exploratory laparotomy in Hodgkin's disease in the Middle East. 11th Intl Cancer Cong, Part 1-2:276, 1974.
  5. Salem PA and Hajj A. Role of the hospital-based cancer registry: The experience of the American University of Beirut Hospital. 6th Scien Mtg Leb Assoc for Advancement of Science, Beirut, Proceedings of the meeting, p 291, 1974.
  6. Salem PA, Hajj A, Alami S, Nassar V. Mediterranean abdominal lymphoma. 3rd Intl Symp on Detection and Prevention of Cancer, New York, 1976.
  7. Salem PA, Sinno B, Hajj A, Kuzhaya S. High dose intermittent therapy with DTIC in melanoma and other solid tumors. Am Assoc Cancer Res, Abstract #462, 17:116, 1976.
  8. Salem PA and Nassar VH. Primary small intestine lymphoma with malabsorption -- A distinct clinicopathological entity. Am Soc Clin Oncol, Abstract #C-138, 17:271, 1976.
  9. Salem PA and Parsi M. Combination chemotherapy in the treatment of inflammatory breast cancer. Am Assoc Cancer Res, Abstract #82, 18:21, 1977.
  10. Salem PA and Risk G. Hepatic arterial combination chemotherapy in the treatment of primary malignant lymphomas in the liver. (Abstract) Am Soc Clin Oncol, 18:268, 1977.
  11. Salem PA, Bodey G, Freireich E. Current clinical status of cis-dichlorodiammineplatinum II (DDP) in cancer therapy. Annual Meeting, Texas Medical Assoc, 1977.
  12. Salem PA and Tarraf F. Lebanon's experience with a hospital-based cancer registry. 1st Middle East Cancer Conference, Egypt, 1977.
  13. Salem PA, Nassar V, Hajj A, Salem A, Alami A. The role of staging laparotomy in the total management of primary small intestinal lymphoma. 1st Middle East Cancer Conference, Egypt, 1977.
  14. Hall, Salem PA, Benjamin R, Lu K, Loo TL, Murphy W, Wharton JT, Bodey G. Continuous intravenous infusion (civi) of cis-dichlorodiammine-platinum II (DDP): A clinical toxicologic and pharmacologic study. Am Soc Clin Oncol, Abstract #C-441, 19:417, 1978.
  15. Salem PA, Parsi M, Tavelian S. Intra-hepatic arterial combination chemotherapy with adriamycin, cyclophosphamide and 5-fluorouracil in the treatment of metastatic liver disease from breast cancer. Am Assoc Cancer Res, Abstract #45, 19:12, 1978.
  16. Salem PA, Haddad F, Brihi E, Issa P. Treatment of glioblastoma multiforme with CCNU and brain irradiation. Am Soc Clin Oncol, Abstract #C-56, 19:320, 1978.
  17. Salem PA. Problems related to the study of primary small intestinal lymphomas in the Middle East. (Abstract) 3rd Intl Symp of Oncol, Tehran, 1978.
  18. Salem PA, Nassar V, Hajj A, Alami S, Salem A. Mediterranean abdominal lymphoma -- the experience of the American University of Beirut. 12th Intl Cancer Cong, Abstract #W62/6, 12:954, 1978.
  19. Hajj A, Salem PA, Nassar V, Issa P, Brihi E, Salem A. Survival of patients with Mediterranean abdominal lymphoma. 12th Intl Cancer Cong, Abstract #W61/19, 12:949, 1978.
  20. Salem PA, Mouradian S, Badran G. Combination chemotherapy in the treatment of advanced Mediterranean abdominal lymphoma. Am Soc Clin Oncol, Abstract #C-109, 20:317, 1979.
  21. Salem PA, Jabboury K, Khalyl M. Cis-dichlorodiammineplatinum by 5-day continuous infusion-toxicity pattern. Am Assoc Cancer Res, Abstract #336, 20:84, 1979.
  22. Salem PA, Jabboury K, Khalyl M. Further studies with cis-dichlorodiammineplatinum as a continuous 5-day infusion. Am Assoc Cancer Res, Abstract #716, 21:179, 1980.
  23. Salem PA, Nassar V, Alami S, Jabboury K, Khalyl M. Immuno-proliferative small intestinal disease -- A potentially preventable disease. 4th Intl Symp on Prevention and Detection of Cancer, 3:448, 1980.
  24. Salem PA, Jabboury K, Hashimi L, Khalyl M. Preliminary studies with vindesine. (Abstract) Am Soc Clin Oncol, 22:435, 1981.
  25. Salem PA, Khalyl M, Rizk G, Jabboury K, Hashimi L. Intra-hepatic artery infusion chemotherapy with cis-platinum in the treatment of metastatic liver from breast cancer. (Abstract) Am Assoc Cancer Res, 22:191, 1981.
  26. Salem PA, Nassar V, Allam C, Alami S, Salem A, Jabboury K, Hashimi L, Khalyl M. Immunoproliferative small intestinal disease -- A new and distinct form of malignant lymphoma. Intl Conf on Malignant Lymphoma -- Current Status and Prospects, Lugano, 1981.
  27. Salem PA, Nassar V, Allan C, Salem A, Jabboury K, Hashimi L, Khalyl M. Mediterranean abdominal lymphoma -- An update. (Abstract) 13th Intl Cancer Conf, Seattle, 1982.
  28. Hashimi L, Allam C, Khalyl M, Issa P, Brihi E, Salem PA. Primary gastrointestinal lymphomas -- The experience of an academic referral center in the Middle East. (Abstract) 13th Intl Cancer Conf, Seattle, 1982.
  29. Salem PA, Issa P, Brihi E, Obeid S, Allam C, Tarraf F, Khalyl M. The cancer program at the American University of Beirut Medical Center -- A model for the establishment of future cancer programs in the Middle East. (Abstract) 13th Intl Cancer Conf, Seattle, 1982.
  30. Hannoun J, Habboubi N, Allam C, Khalyl M, Brihi E, Issa P, Salem PA. Large cell lymphoma presenting as primary breast cancer --A report of four cases. (Abstract) 13th Intl Cancer Conf, Seattle, 1982.
  31. Hashimi L, Anaissie E, Allam C, Khalyl M, Salem PA. Childhood abdominal lymphomas in the Middle East. (Abstract) 2nd Intl Conf on Malignant Lymphoma, Lugano, 1984.
  32. Anaissie E, Geha S, Allam C, Jabboury K, Obeid M, Issa P, Brihi E, Khalyl M, Shikhani A, Samara M, Salem PA. Waldeyer's Ring lymphomas -- A study of 83 cases from the Middle East. 2nd Intl Conf on Malignant Lymphoma, Lugano, 1984.
  33. Salem PA, Hashimi L, Anaissie E, Khalyl M, Allam C. Primary intestinal lymphoma of adults in the Middle East. (Abstract) 4th Mediterranean Conf of Chemo, Rhodes, 1984.
  34. Shikhani A, Anaissie E, Allam C, Salem PA, Samara M. Primary lymphoma of the salivary glands -- Report of 4 cases and review of the literature. Intl Conf on Head and Neck Cancer, Baltimore, 1984.
  35. Salem PA, Habboubi N, Anaissie E, Brihi E, Issa P, Abbas J, Khalyl M. Cis-dichlorodiammineplatinum (II) is effective in the treatment of anal squamous cell carcinoma. (Abstract) Am Soc Clin Oncol, 4:78, 1985.
  36. Annaissie E, Geha S, Allam C, Jabboury K, Hashimi L, Khalyl M, Salem PA. Non-Hodgkin's lymphoma in the Middle East. Am Assoc Cancer Res, Abstract #580, 26:147, 1985.
  37. Salem PA, Khalyl M, Jabboury K, Hashimi L. The 5-day continuous infusion of cisplatinum -- An update on toxicity pattern. (Abstract) 14th Intl Conf of Chemo, Kyoto, 1985.
  38. Salem PA, Allam C, Hashimi L, Anaissie E, Khalyl M. Immunoproliferative small intestine disease -- A disease of the Middle East and Mediterranean countries. (Abstract) 14th Intl Cancer Conf, Budapest, 1986.
  39. Anaissie E, Geha S, Allam C, Jabboury K, Hashimi L, Khalyl M, Salem PA. Primary extra-nodal lymphoma in the Middle East. (Abstract) 14th Intl Cancer Conf, Budapest, 1986.
  40. Salem PA: Immunoproliferative small intestine disease -- The only human lymphoma associated with a tumoral marker. 2 Congresso Internazionale Sui Markers Tumorali, Napoli, p. 63, 1986.
  41. Salem PA, Anaissie E, Geha S, et al. Primary extranodal lymphoma in the Middle East. (Abstract) 3rd Intl Conf on Malignant Lymphoma, Lugano, 1987.
  42. Salem PA. Immunoproliferative small intestinal disease: New concepts in pathology. (Abstract) Am Soc Clin Oncol, 6:244, 1987.
  43. Salem PA, Hashimi L, Allam C. Immunoproliferative small intestinal disease -- The only human lymphoma associated with a biological marker and a recognizable benign phase. Am Soc Clin Oncol, Abstract #A945, 7:244, 1988.
  44. Jabboury K, Hortobagyi G, Holmes FA, Frye D, Salem PA. Phase II gallium nitrate infusion in breast cancer. Am Assoc Cancer Res, Abstract #1446, 29:363, 1988.
  45. Salem PA, Zukiwski A, Bunn P, Robinson W, Lamb R, Benjamin RS, Spitler L, Scannon P, Ackerman S. Treatment of advanced metastatic melanoma using single dose murine monoclonal antibody ricin A chain immunotoxin using dose escalation. Phase I study. (Abstract) 1st Intl Symp on Immunotoxins, p. 55, 1988.
  46. Salem PA, Zukiwski A, Robinson W, Bunn P, Lamb R, Benjamin RS, Spitler L, Wedel N, Ackerman S. Treatment of advanced metastatic melanoma using single dose murine monoclonal antibody -- Ricin A chain immunotoxin using dose escalation. A phase I study. Am Assoc Cancer Res, Abstract #1147, 30:288, 1989.
  47. Salem PA, Zukiwski A, Benjamin RS, Wallace S, Levitt D, Mavligit G. Arterial infusion of interleukin-2 (IL-2) for treatment of hepatic metastases from GI leiomyosarcoma: Predisposition of hypersensitivity to iodine-containing media. Am Soc Clin Oncol, Abstract #1252, 8:322, 1989.
  48. Legha S, Papadopoulos N, Plager C, Usakewicz J, Salem PA, Nicaise C, Benjamin R. A comparative evaluation of the uroprotective effect of mercaptoethane sulfonate (MESNA) and N-acetylcysteine (NAC) in sarcoma patients treated with ifosfamide. Am Soc Clin Onc, Abstract #1205, 9:311, 1990.
  49. Linke KA, Benjamin RS, Evans HL, Salem PA, and Benjamin RS: Phase I-II study of IL-2 used as a continuous infusion in patients with metastatic melanoma. Am Assoc Cancer Res, Abstract #A1217, 31:176, 1990, and Am Soc Clin Onc, 9:217, 1990.
  50. Legha S, Fiana M, Plager C, Papadopoulos N, Salem PA, Benjamin RS. Phase I-II study of IL-2 used as a continuous infusion in patients with metastatic melanoma. Am Assoc Cancer Res, Abstract #1047, 31:176, 1990.
  51. Salem PA, Steiger S, Benjamin RS. Phase II study of THP-adriamycin (Pirarubicin) and DTIC in advanced soft tissue sarcomas. (Abstract) 3rd Intl Conf on Neo-adjuvant Chemotherapy, France, p 24, February 6-9, 1991.
  52. Vadhan-Raj S, Broxmeyer HE, Hittelman WN, Papadopoulos NE, Pager C, Salem PA, Gutterman JU, Benjamin RS. Abrogating chemotherapy CT-induced myelosuppression by GM-CSF: Optimizing the schedule. Am Soc Clin Oncol, Abstract #1241, 10:349, 1991.
  53. Salem PA, Steiger S, Benjamin RS. Phase II study of THP-Adriamycin (pirarubicin) and DTIC in advanced soft tissue sarcomas. Am Soc Clin Oncol, Abstract #1249, 10:351, 1991.
  54. Plager C, Papadopoulos NEJ, Salem PA, Benjamin RS. Adriamycin-based chemotherapy for leiomyosarcoma of the stomach and small bowel. Am Soc Clin Oncol, Abstract #1251, 10:352, 1991.
  55. Patel SR, Legha SS, Salem PA, Plager C, Papadopoulos NEJ, Benjamin RS. Evaluation of Ifosfamide in metastatic leiomyosarcomas of gastrointestinal (GI) origin. Am Soc Clin Oncol, Abstract #1252, 10:352, 1991.
  56. Salem PA, Benjamin RS, Howard J, Gutterman JU. Phase II trial of recombinant interferon alpha 2-b in the treatment of advanced metastatic and refractory sarcomas. Am Assoc Cancer Res, Abstract #1192, 32:200, 1991.
  57. Salem PA, El-Hashimi L, Anaissie E, Geha S, Habboubi N, Ibrahim N, Khalyl M, Allam C. Primary small intestinal lymphoma in adults. A comparative study of IPSID versus non-IPSID in the Middle East. 8th Mediterranean Congr of Chemo, Athens, J Chemother, May 24-29, 1992.
  58. Salem PA. Advances in the treatment of soft tissue sarcomas. 8th Mediterranean Congr of Chemo, Athens, J Chemother, May 24-29, 1992.
  59. Salem PA. The Emerging Role of Immunotherapy in the treatment of cancer. Keynote Speech. VIII ARTOI International Conference, New Frontiers of Integrated Oncology from Research to Integration. Florence, Italy November 11-13, 2016.
  60. Salem PA., Jabboury K, Stenoien R, Wheeler T, Valerio MR. Personalized Multimodality Therapy with Immune Checkpoint Inhibitors (ICI), Chemotherapy (CT), and Targeted Treatment (TT) in Advanced Refractory Cancer. Published as an abstract in the 2019 ASCO Annual Meeting Proceedings. Journal of Clinical Oncology, 37, #25 supplement. (e14254).
  61. Salem PA., Jabboury K, Stenoien R, Wheeler T. Personalized Multimodality Therapy with Immune Checkpoint Inhibitors (ICI), Chemotherapy (CT), and Targeted Treatment (TT) in Advanced Refractory Cancer. Published as an abstract in the 2020 ASCO Annual Meeting Proceedings. Journal of Clinical Oncology; volume 38; issue 15; S supplement. (e15150).
  62. Philip A. Salem, Khaled W. Jabboury, William G.B. McCallum, Randall A. Stenoien, and Thomas M. Wheeler. Personalized multimodality therapy with immune checkpoint inhibitors, chemotherapy, and targeted treatment (ICTriplex) in advanced/refractory cancer. Published as an abstract in the 2022 ASCO Annual Meeting Proceedings. Journal of Clinical Oncology; Volume 40; Number 16; S supplement. (e14590).
  63. Paolo Angelini*, Carlo Uribe, Philip A. Salem, Robert Bagwell. Case Report: Can critical coronary artery disease coexist with transient takotsubo cardiomyopathy? How does spasm interrelate? Clinical research in cardiology. Tex Heart Inst J. 2023 Mar 1;50(2):e227941.doi: 10.14503/THIJ-22-7941.
  64. Philip A. Salem, Lorenzo Gensini, William G.B. McCallum, John Hanna, Thomas M. Wheeler, Randall A. Stenoien, Khaled W. Jabboury; Efficacy of the combination of immune checkpoint inhibitors, chemotherapy, and targeted treatment in advanced/refractory cancer. Accepted for Poster presentation at ASCO Breakthrough, Yokohama, Japan, August 8-10, 2024, and was published in a supplement of The Journal of Clinical Oncology (Volume 42, Number 23 – suppl 41).